tagline Fall 2012
- TAG at 20 - Part II: On a Darkling Plain—The Years of Despair
Before the Discovery of HAART
This is the second in a series looking back at the first two decades of TAG’s work to speed up AIDS research. In Part I: TAG’s early campaigns to reform the National Institutes of Health (NIH) AIDS research, boost the federal budget, and revitalize HIV basic science research. Here we look at the clinical science of AIDS before the discovery of highly active antiretroviral therapy (HAART) in 1995–96, and how TAG responded to the needs of people with AIDS.
- Only Stronger U.S. Leadership Can End the AIDS Epidemic
Existing treatment and prevention techniques could prevent millions of new HIV infections and deaths from AIDS—but only if Obama sustains funding.
This article was first published on 24 July 2012 in theAtlantic.com
- Cure-Related Research at AIDS 2012
At the recent International AIDS Conference in Washington, D.C. (AIDS 2012), the research effort to develop a cure for HIV infection attained a higher profile than it ever has in the past. At a press conference on July 19, the International AIDS Society (IAS) officially launched its Global Strategy “Towards an HIV Cure,” in conjunction with a two-day symposium that immediately preceded the main conference.
- The Future of TB in the United States: Going, or Growing?
This summer, Treatment Action Group (TAG) and its partners in fighting tuberculosis (TB) issued a call for zero TB deaths, zero new TB infections, and zero suffering from TB. Yet the U.S., long a leader in TB elimination efforts, is in jeopardy of losing ground in the struggle to get to zero. Drug shortages, coupled with financial obstacles, are threatening the success of TB programs nationwide. TB, long forgotten by the general public and by many policy makers, still affects the U.S., with over 10,000 new cases in 2011.
- Getting to Zero—Join the Movement!
In May 2012, a group of activists, researchers, clinicians, implementers, policy makers, and foundation and government staff working to stop TB met in Cambridge, Massachusetts. During their three-day meeting, the group gave birth to a global TB strategy focused on a new target: zero TB deaths, zero new TB infections, and zero TB suffering and stigma. To this end, they created the Zero Declaration, which has already been signed by 500 institutions and individuals.
- GeneXpert Rapid TB Test Price Reduced in Historic Agreement
After months of political wrangling, in early July 2012, an agreement to reduce the price of the GeneXpert MTB/RIF rapid test for tuberculosis (TB) was reached between the manufacturer, Cepheid, and pooled purchasers UNITAID, PEPFAR, USAID, and the Bill & Melinda Gates Foundation. GeneXpert was codeveloped by Cepheid, the Foundation for Innovative New Diagnostics (FIND), and the University of Medicine and Dentistry of New Jersey (UNMDJ). It accurately diagnoses both TB and some common rifampin drug-resistance mutations within two hours.